Biocardia Stock Pattern Recognition Thrusting Pattern
| BCDA Stock | USD 1.27 -0.01 -0.78% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was eleven with a total number of output elements of fifty. The function did not return any valid pattern recognition events for the selected time horizon. The Thrusting Pattern describes Biocardia bearish continuation trend.
Biocardia Technical Analysis Modules
Most technical analysis of Biocardia help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Biocardia from various momentum indicators to cycle indicators. When you analyze Biocardia charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. A high-level view of Biocardia emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 5.13. Biocardia has market cap of 13.48 M, ROE of -3.17%.
Methodology
Unless otherwise specified, financial data for Biocardia is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Biocardia (USA Stocks:BCDA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Biocardia may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biocardia in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biocardia's short interest history, or implied volatility extrapolated from Biocardia options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | FinTech Invested over 60 shares | |
 | Artificial Intelligence Invested few shares | |
 | Power Assets Invested over 200 shares | |
 | Dividend Beast Invested over 40 shares | |
 | Hedge Favorites Invested over 20 shares | |
 | Driverless Cars Invested over 200 shares | |
 | Momentum Invested few shares | |
 | Adviser Favorites Invested few shares |
More Resources for Biocardia Stock Analysis
A structured review of Biocardia often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Biocardia Stock in context:Biocardia has market cap of 13.48 M, ROE of -3.17%. Use Trending Equities to explore allocation context. This includes a position in Biocardia across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. For more information on how to buy Biocardia Stock please use our How to Buy Biocardia Stock guide.Analysis related to Biocardia should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
The market value of Biocardia is measured differently than book value, which reflects Biocardia accounting equity. Biocardia's market capitalization is 13.48 M. With a P/B ratio of 5.13, the market values Biocardia well above its book equity. Enterprise value stands at 8.83 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Biocardia's intrinsic value and market price are different measures derived from different inputs. For Biocardia, key inputs include a P/B ratio of 5.13, ROE of -3.17%, and revenue of 58 K. Trading price represents the transaction level agreed by market participants.